Substrates for peptidase M12.208: ADAM8 peptidase
Peptide and protein substrates that are thought to be physiologically relevant are indicated by P. Peptide and protein substrates that are thought to be pathologically relevant are indicated by D. Peptide and protein substrates that are not physiologically relevant are indicated by N. Synthetic substrates are indicated by S. Click on the symbol to show only physiological, non-physiological or synthetic substrates, or here to display all substrates. How cleavage sites have been identified are indicated by the following evidence codes: NT = N-terminal sequencing, MS = mass spectroscopy, MU = mutation, CS = consensus sequence, LC = liquid chromatography. To see all annotated cleavages for a protein substrate, click on the UniProt Accession.
| Substrate | Uniprot | Residue range | Cleavage Site | Cleavage type | Evidence | P4 | P3 | P2 | P1 | P1' | P2' | P3' | P4' | Reference | CutDB | MERNUM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADAM8 peptidase | Q05910 | 17-826 | peptide-Val401+Gly-peptide | P | Asn | Arg | Phe | Val | Gly | Gly | Pro | Val | Schlomann et al., 2002 | 19849 | ||
| amyloid beta A4 protein | P05067 | 18-770 | peptide-His685+Gln-peptide | P | Glu | Val | His | His | Gln | Lys | Leu | Val | Amour et al., 2002 | |||
| c-{kit} ligand-1 cleavage site peptide | Leu-Pro-Pro-Val-Ala-Ala+Ser-Ser-Leu-Arg | N | Pro | Val | Ala | Ala | Ser | Ser | Leu | Arg | Amour et al., 2002 | |||||
| CatE1 | EDANS-Lys-Pro-Ala-Lys-Phe+Phe-Arg-Leu-Lys(dabcyl) | N | Pro | Ala | Lys | Phe | Phe | Arg | Leu | DbK | Fourie et al., 2003 | |||||
| CatE2 | EDANS-Lys-Pro-Ala-Ala-Phe+Phe-Arg-Leu-Lys(dabcyl) | N | Pro | Ala | Ala | Phe | Phe | Arg | Leu | DbK | Fourie et al., 2003 | |||||
| CD27L | EDANS-Arg-PhAla-Gln-Ala+Gln-Gln-Gln-Leu-Pro-Lys(dabcyl) | N | Phe | Ala | Gln | Ala | Gln | Gln | Gln | Leu | Fourie et al., 2003 | |||||
| Dabcyl-Leu-Ala-Gln-Ala-HPh-Arg-Ser-Lys(Fam)-NH2 | Dabcyl-Leu-Ala-Gln-Ala+HPh-Arg-Ser-Lys(Fam)-NH2 | S | Leu | Ala | Gln | Ala | HPh | Arg | Ser | LyN | Moss & Rasmussen, 2007 | |||||
| Dabcyl-Pro-Arg-Ala-Ala-Ala-hPhe-Thr-Ser-Pro-Lys(FAM)-NH2 | Dabcyl-Pro-Arg-Ala-Ala-Ala+homoPhe-Thr-Ser-Pro-Lys(FAM)-NH2 | S | Arg | Ala | Ala | Ala | HPh | Thr | Ser | Pro | Moss et al., 2016 | |||||
| Dabcyl-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(Fam)-NH2 | Dabcyl-Pro-Cha-Gly+Cys(Me)-His-Ala-Lys(Fam)-NH2 | S | Dab | Pro | Cha | Gly | CyM | His | Ala | LyN | Moss & Rasmussen, 2007 | |||||
| Dabcyl-Ser-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Lys(FAM)-NH2 | Dabcyl-Ser-Pro-Leu-Ala-Gln-Ala+Val-Arg-Ser-Ser-Lys(FAM)-NH2 | S | Leu | Ala | Gln | Ala | Val | Arg | Ser | Ser | Moss et al., 2016 | |||||
| Dnp-Arg-Ala-Glu-Gln-Gln-Arg-Leu-Lys-Ser-Gln-Asp-Leu | P06734 | 96-107 | Dnp-Arg-Ala-Glu-Gln+Gln-Arg-Leu-Lys-Ser-Gln-Asp-Leu | S | Arg | Ala | Glu | Gln | Gln | Arg | Leu | Lys | Lemieux et al., 2007 | 20044 | ||
| Dnp-Arg-Ala-Glu-Gln-Gln-Arg-Leu-Lys-Ser-Gln-Asp-Leu | P06734 | 96-107 | Dnp-Arg-Ala-Glu+Gln-Gln-Arg-Leu-Lys-Ser-Gln-Asp-Leu | S | Dnp | Arg | Ala | Glu | Gln | Gln | Arg | Leu | Lemieux et al., 2007 | 20045 | ||
| Dnp-His-Gly-Asp-Gln-Met-Ala-Gln-Lys-Ser-Gln-Ser-Thr | P06734 | 75-86 | Dnp-His-Gly-Asp-Gln-Met-Ala+Gln-Lys-Ser-Gln-Ser-Thr | S | Asp | Gln | Met | Ala | Gln | Lys | Ser | Gln | Lemieux et al., 2007 | 20046 | ||
| fibronectin | P02751 | 32-2386 | peptide-Ala292+Val-peptide | P | NT | Val | Arg | Ala | Ala | Val | Tyr | Gln | Pro | Zack et al., 2009 | ||
| Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(TF)-Ser-Lys(DABCYL) | Glu(EDANS)-Pro-Leu-Ala-Gln-Ala+Val-Arg-Ser-Ser(TF)-Ser-Lys(DABCYL) | S | Leu | Ala | Gln | Ala | Val | Arg | Ser | Ser | Minond et al., 2012 | |||||
| Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(TF)-Ser-Lys(DABCYL) | Glu(EDANS)-Pro-Leu-Ala-Gln+Ala-Val-Arg-Ser-Ser(TF)-Ser-Lys(DABCYL) | S | Pro | Leu | Ala | Gln | Ala | Val | Arg | Ser | Minond et al., 2012 | |||||
| Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(TF)-Ser-Lys(DABCYL) | Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val+Arg-Ser-Ser(TF)-Ser-Lys(DABCYL) | S | Ala | Gln | Ala | Val | Arg | Ser | Ser | Ser | Minond et al., 2012 | |||||
| Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Lys(DABCYL) | Glu(EDANS)-Pro-Leu-Ala-Gln-Ala+Val-Arg-Ser-Ser(TF)-Ser-Lys(DABCYL) | S | Leu | Ala | Gln | Ala | Val | Arg | Ser | Ser | Minond et al., 2012 | |||||
| IL-1Rc | Thr-Val-Lys-Glu-Ala-Ser+Ser-Thr-Phe-Ser-Trp-Gky | N | Lys | Glu | Ala | Ser | Ser | Thr | Phe | Ser | Amour et al., 2002 | |||||
| kit ligand | P20826 | 26-273 | peptide-Ala190+Ser-peptide | P | Pro | Val | Ala | Ala | Ser | Ser | Leu | Arg | Kawaguchi et al., 2007 | 20080 | ||
| myelin basic protein | P04370 | 1-250 | peptide-Pro73+Gln-peptide | P | Gly | Ser | Leu | Pro | Gln | Lys | Ser | Gln | Amour et al., 2002 | |||
| myelin basic protein | P02687 | 1-169 | peptide-Pro71+Gln-peptide | P | Gly | Ser | Leu | Pro | Gln | Lys | Ala | Gln | Schlomann et al., 2002 | 19850 | ||
| neural cell adhesion molecule L1-like protein | P70232 | 26-1209 | peptide-Pro1040+Gly-peptide | P | NT | Val | Leu | Val | Pro | Gly | Ala | Glu | His | Naus et al., 2004 | 19928 | |
| neural cell adhesion molecule L1-like protein | P70232 | 26-1209 | peptide-Pro753+Gln-peptide | P | NT | Ser | Trp | Lys | Pro | Gln | Gly | Ala | Pro | Naus et al., 2004 | 19929 | |
| TNFalpha | EDANS-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser+Ser-Ser-Lys(dabcyl) | N | Ala | Val | Arg | Ser | Ser | Ser | DbK | - | Fourie et al., 2003 | |||||
| TNFalpha | Ser-Pro-Leu-Ala+Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys | N | Ser | Pro | Leu | Ala | Gln | Ala | Val | Arg | Amour et al., 2002 | |||||
| TNFalpha | Ser-Pro-Leu-Ala-Gln-Ala+Val-Arg-Ser-Ser-Ser-Arg-Lys | N | Leu | Ala | Gln | Ala | Val | Arg | Ser | Ser | Amour et al., 2002 | |||||
| tumor necrosis factor | P01375 | 1-233 | peptide-Ala74+Gln-peptide | P | Ser | Pro | Leu | Ala | Gln | Ala | Val | Arg | Amour et al., 2002 | |||
| tumor necrosis factor | P01375 | 1-233 | peptide-Ala76+Val-peptide | P | Leu | Ala | Gln | Ala | Val | Arg | Ser | Ser | Amour et al., 2002 |
